Business
Subscription of shares by Institut Mérieux
Subscription of shares by Institut Mérieux.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \n \n \nSubscription of shares by Institut Mérieux\nOxford, UK - 18 June 2024: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\", \"OXB\" or \"the Company\"), a quality and innovation-led cell and gene therapy CDMO, today announces that an application has been made to the Financial Conduct Authority and the London Stock Exchange for the admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for the listing of 5,201,107 new ordinary shares of 50 pence each (\"Admission\"), representing 4.9% of the Company's enlarged issued share capital following the issue of such new ordinary shares. The new ordinary shares will be issued on a non pre-emptive basis utilising the authority granted at the Group's 2023 AGM.\nThe Admission is in respect of a EUR 20 million investment (£16.9 million) by TSGH SAS, a subsidiary of Institut Mérieux SA (\"Institut Mérieux\") which has been made at a share price of 325p per ordinary share, being the 30-day VWAP to closing on 17 June 2024. As previously communicated, this investment follows Oxford Biomedica's acquisition of ABL Europe SAS, (since renamed Oxford Biomedica (France) SAS (\"OXB France\")) from Institut Mérieux, which was completed on 29 January 2024. The announcement can be found here. The acquisition of OXB France has enhanced OXB's bioprocessing and manufacturing footprint in the EU, strengthening the Group's multi-vector, multi-site model and adding specialised expertise in the development and manufacturing of solutions for biotech and biopharma companies.\n \nThe Admission is expected to occur on 19 June 2024. Following Admission and following the previously announced transaction and purchases in the open market, Institut Mérieux will hold a 10.9% stake in Oxford Biomedica, making it a major, long-term shareholder and further underpinning conviction in OXB's strategy.\n \n-Ends-\n \n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\n \nOxford Biomedica plc:\nNatalie Walter, Company Secretary\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \n \nABOUT OXFORD BIOMEDICA\n \nOxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...